Molina Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Oct 27, 2022 and accepted by EDGAR at Oct 27, 2022, 10:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $7.93bn | us-gaap:Revenues |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $23.75bn | us-gaap:Revenues |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $6.75bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $20.18bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2022-07-01 to 2022-09-30 | $335.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | $1.07bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $28.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $83.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $77.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $249.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $230.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | $736.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $3.95 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | $12.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $4.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | $12.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 58,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 58,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $985.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $81.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2022-01-01 to 2022-09-30 | $200.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-09-30 | $4.24bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $10.49bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $12.79bn | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $7.24bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $9.75bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $2.17bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-09-30 | $3.04bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001179929-22-000172. Last ingested by Listed: Oct 30, 2026, 13:54 ET. Listed shows no prices and gives no investment advice.